Top Story Today
Vertex Bet $10 Billion on Hormones. The Math Requires Some Optimism.
Vertex is paying $10 billion in cash to acquire Crinetics Pharmaceuticals, a company that brought in just $10.7 million last quarter. The 102% premium is Vertex's largest deal ever, adding two endocrine drugs (a daily pill for acromegaly and a steroid-sparing therapy for congenital adrenal hyperplasia) that the company says could hit $5 billion in combined peak sales. Analysts are split: some call the price justified by Vertex's commercialization muscle, others warn it only works if everything goes right. The deal won't add to Vertex's bottom line until 2029.
Why it matters: This acquisition marks Vertex's boldest diversification move yet, building endocrinology as a fifth therapeutic pillar alongside CF, pain, gene editing, and kidney disease. Whether it looks brilliant or reckless depends entirely on execution over the next three to five years.
Read more →Clinical Breakthroughs
The Cancer Protein Nobody Could Drug for 40 Years Just Got Drugged
The FDA accepted Revolution Medicines' application for daraxonrasib, the first drug to block active RAS across multiple mutations, in previously treated metastatic pancreatic cancer. Phase 3 data showed median survival of 13.2 months versus 6.7 months on chemo, a 60% reduction in the risk of death. The agency selected it for an accelerated review that could compress the timeline to just one or two months.
Read more →Moderna Launches Phase 3 Bird Flu Vaccine Trial Before Any Pandemic
Moderna kicked off a 4,000-person Phase 3 trial for its mRNA bird flu vaccine, backed by $54.3 million from CEPI. Interim data already show 82.7% efficacy against H5N1, and early-phase results pushed protective antibody levels from 2.1% to 97.8% after two doses. With avian flu circulating in over 1,070 U.S. dairy herds, this is pandemic prep before the pandemic.
Read more →Kailera's Obesity Pill Works, But Seven in Ten Patients Got Nauseous
Kailera's oral GLP-1 pill delivered roughly 11% weight loss in a Phase 3 China trial, but 70% of patients experienced nausea and 67-69% had vomiting. Shares dropped 10%. With Lilly's orforglipron showing 12.4% weight loss and far milder GI side effects, Kailera needs a serious dosing redesign to compete.
Read more →Regulatory & Transparency
The FDA Quietly Stopped Publishing Drug Rejection Letters
After an anonymous pharma company filed a citizen petition, the FDA paused its policy of publicly releasing Complete Response Letters, the detailed documents explaining why drugs get rejected. The transparency initiative lasted just nine months. Investors, clinicians, and small biotechs have lost a critical window into regulatory decision-making, with no timeline for when (or whether) the letters will return.
Read more →Roche Killed Two Huntington's Programs in One Day. The Field Is Reeling.
Roche terminated tominersen and RG6496 on the same day, ending a roughly decade-long Huntington's partnership with Ionis. Tominersen nailed its biomarkers (lowering the toxic protein as designed) but patients showed zero clinical improvement, a cautionary tale about the gap between hitting a target and helping a patient. Ionis shares fell about 8% on the news.
Read more →Deals & Global Markets
Zymeworks Is Spending $929M on a Company Whose Lead Drug Failed Three Times
Zymeworks will acquire Theravance Biopharma for $929 million, but the real prize isn't the thrice-failed ampreloxetine; it's a portfolio of royalty cash flows from YUPELRI and Trelegy milestones, plus $2.5 billion in Irish tax attributes. The deal signals biotech's growing appetite for predictable income over pipeline moonshots.
Read more →Novo Nordisk's Once-Weekly Insulin Launches in India, Cheaper Than Daily Shots
Novo launched Awiqli, the world's first once-weekly insulin, in India at prices 30-40% cheaper per unit than existing daily alternatives. In a country with 100 million diabetics where only 30% hit their blood sugar targets, cutting injections from 365 to 52 per year could be transformative for adherence.
Read more →